search
AVAX
Trends
- 1Novavax booster draws milder side effect reports than mRNA shots●# Novavax +22 hours: no side effects other than injection site soreness. Which is somewhat worse than the flu shot I als
A person who received the Novavax COVID-19 vaccine reported no side effects 22 hours after the shot, apart from soreness at the injection site, which they described as slightly worse than the flu jab they received at the same time. They noted that mRNA vaccines usually left them fatigued and chilled for an evening. The account adds to ongoing personal comparisons of protein-based versus mRNA vaccine side effects.
- 2
Novavax, the Maryland-based vaccine maker, is seeing renewed interest in its shares, with its stock quote, price history and latest news being tracked by investors on finance platforms. The company, known for its COVID-19 vaccine, remains a focus for traders watching biotech and pandemic-related stocks, though no specific new development is detailed in the coverage.
- 3Nuravax Reports Phase 1 Results for Alzheimer's Vaccine AV-1959R▼Nuravax and Institute for Molecular Medicine Announce Publication of Phase 1 Results for AV-1959R Amyloid-Beta Vaccine
Nuravax and the Institute for Molecular Medicine have announced the publication of Phase 1 clinical trial results for AV-1959R, an amyloid-beta vaccine candidate aimed at Alzheimer's disease. The companies say the results are now public, marking an early-stage milestone for the experimental immunotherapy aimed at clearing amyloid plaques.
- 4Avalanche's AVAX Surges Nearly 50% in a Month●AVAX Up Nearly 50% in Four Weeks, Outpacing Bitcoin and Ether Avalanche's AVAX gained 49.7% in 28 days, far ahead of bit
Avalanche's AVAX token has climbed 49.7% over the past 28 days, dramatically outperforming bitcoin's roughly 9% gain and ether's 2.3%. The rally coincides with Avalanche's Helicon upgrade, which shortened validator commitment periods on the network. Traders and analysts are watching whether the momentum can continue or if the token is overheated relative to the broader crypto market.
- 5AVAX surges 50% in a month, beating Bitcoin and Ether●Avalanche's AVAX gains 50% in four weeks, outpacing Bitcoin and Ether
Avalanche's AVAX token has climbed roughly 50% over the past four weeks, a gain that outpaces both Bitcoin and Ether over the same period. The rally has put Avalanche back in focus among crypto traders, who are weighing whether the altcoin's momentum can continue or represents a short-lived speculative run.
- 6First Participants Dosed in Phase 1 Trial of Alzheimer's Vaccine Candidate AV-1980R●Institute for Molecular Medicine and Nuravax Announce First Participants Dosed in Phase 1 TAURUS-1980 Study of AV-1980R
The Institute for Molecular Medicine and Nuravax have announced that the first participants have been dosed in TAURUS-1980, a Phase 1 clinical trial of AV-1980R. The early-stage study marks the first time the vaccine candidate has been tested in humans, a key step toward evaluating its safety and immune response. Details on trial size, locations and timelines have not yet been widely reported.